​

Burning Rock Biotech Limited

NasdaqGM:BNR Stock Report

Market Cap: US$49.6m

Burning Rock Biotech (BNR) Stock Overview

Develops and sells cancer therapy selection tests in the People's Republic of China and the United States. More details

BNR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings have grown 0.7% per year over the past 5 years

Risk Analysis

Volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($50M)


BNR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Burning Rock Biotech Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Burning Rock Biotech
Historical stock prices
Current Share PriceUS$4.70
52 Week HighUS$7.90
52 Week LowUS$2.18
Beta0.75
1 Month Change26.34%
3 Month Change67.86%
1 Year Change-27.69%
3 Year Change-85.08%
5 Year Change-98.03%
Change since IPO-98.09%

Recent News & Updates

Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Jun 21
Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Recent updates

Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Jun 21
Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

Mar 25
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Feb 01
There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jul 12
Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Apr 28
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Dec 23
We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Sep 20
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Aug 31

Burning Rock Localizes As Investors Grow Impatient

Jun 06

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Nov 17

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

Aug 27
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Jul 23
A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

May 13
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

Shareholder Returns

BNRUS BiotechsUS Market
7D11.5%-0.5%1.0%
1Y-27.7%-12.6%15.0%

Return vs Industry: BNR underperformed the US Biotechs industry which returned -10.4% over the past year.

Return vs Market: BNR underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is BNR's price volatile compared to industry and market?
BNR volatility
BNR Average Weekly Movement14.4%
Biotechs Industry Average Movement11.5%
Market Average Movement6.4%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: BNR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BNR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014674Yusheng Hanwww.brbiotech.com

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Burning Rock Biotech Limited Fundamentals Summary

How do Burning Rock Biotech's earnings and revenue compare to its market cap?
BNR fundamental statistics
Market capUS$49.63m
Earnings (TTM)-US$33.23m
Revenue (TTM)US$72.89m
0.7x
P/S Ratio
-1.5x
P/E Ratio

Is BNR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BNR income statement (TTM)
RevenueCN¥523.28m
Cost of RevenueCN¥149.17m
Gross ProfitCN¥374.11m
Other ExpensesCN¥612.68m
Earnings-CN¥238.58m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-22.16
Gross Margin71.49%
Net Profit Margin-45.59%
Debt/Equity Ratio0%

How did BNR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/18 20:32
End of Day Share Price 2025/07/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Burning Rock Biotech Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
null nullChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited